CH Lyon sud

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes	Untreated Myelodysplastic Syndrome	Active, not recruiting	Phase 1 / Phase 2	2026-08-11	NCT05782127
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity	Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder	Recruiting	Not stated	2026-05-06	NCT03003572
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2026-03-17	NCT06353022

Clinical trials